Genocea Biosciences, Inc. (GNCA): New Bullish Coverage

GNCA – H.C. Wainwright & Co. initiates coverage with Buy rating, $5 PT. This price target represents a 350.45% upside over the stock’s previous closing price of $1.11.


Update: As of Dec. 10, 2018, this bullish analyst call has returned -49.55%.


Key Facts Surrounding This News Item


  • GNCA had a POWR Rating of D (Sell) coming into today.
  • GNCA was 6.68% above its 10-Day Moving Average coming into today.
  • GNCA was 9.28% above its 20-Day Moving Average coming into today.
  • GNCA was 8.79% above its 50-Day Moving Average coming into today.
  • GNCA was -0.16% below its 100-Day Moving Average coming into today.
  • GNCA was -62.24% below its 200-Day Moving Average coming into today.
  • GNCA had returned -4.31% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Genocea Biosciences, Inc. (GNCA)


Genocea Biosciences is a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company was founded in 2006 and is based in Cambridge, Massachusetts. View our full GNCA ticker page with ratings, news, and more.

GNCA at a Glance

GNCA Current POWR Rating™
Overall POWR Rating™
GNCA Current Price $0.56 3.45%
More GNCA Ratings, Data, and News

GNCA Price Reaction

The day of this event (Mar. 8, 2018)
GNCA Closing Price$1.20 7.66%
GNCA Volume1,550,300
104.97% from avg
Leading up to this event
GNCA 1-mo return13.27%
After this event
GNCA 1-day return10.48%
GNCA 3-day return5.93%
GNCA 5-day return4.31%

GNCA Price Chart


The Top Stocks For 2019

More Genocea Biosciences, Inc. (GNCA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GNCA News
Page generated in 0.8537 seconds.